Evidence map›Paper›PMID 40993816›Full record

ReviewJournal of translational medicine2025

The role of tetraspanins in organ fibrosis: mechanisms and therapeutic perspectives.

Shengbiao Li, Mi Li, Yi Zhang, Ji Chen, Jiapan Li, Shubo Fu, Jingyan Yi, Rong Li, Gan Qiao, Yang Yu and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shengbiao Li *Department of Medical Cell Biology and Genetics, School of Basic Medical Sciences, Key Laboratory of Medical Electrophysiology, Ministry of Education, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Mi Li *Department of Histology and Embryology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Yi Zhang *Department of Medical Cell Biology and Genetics, School of Basic Medical Sciences, Key Laboratory of Medical Electrophysiology, Ministry of Education, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Ji ChenDepartment of Histology and Embryology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Jiapan LiDepartment of Medical Cell Biology and Genetics, School of Basic Medical Sciences, Key Laboratory of Medical Electrophysiology, Ministry of Education, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Shubo FuDepartment of Medical Cell Biology and Genetics, School of Basic Medical Sciences, Key Laboratory of Medical Electrophysiology, Ministry of Education, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Jingyan YiDepartment of Medical Cell Biology and Genetics, School of Basic Medical Sciences, Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Rong LiBasic Medicine Research Innovation Center for Cardiometabolic Diseases, Luzhou Municipal Key Laboratory of Thrombosis and Vascular Biology, Laboratory for Cardiovascular Pharmacology, Department of Pharmacology, School of Pharmacy, Ministry of Education, Southwest Medical University, Luzhou, 646000, China.
Gan QiaoDepartment of Pharmacology, School of Pharmacy, Nucleic Acid Medicine of Luzhou Key Laboratory, Central Nervous System Drug Key Laboratory of Sichuan Province, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Yang YuDepartment of Cardiology, Key Laboratory of Medical Electrophysiology, Ministry of Education, Institute of Cardiovascular Research, Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Nucleic Acid Medicine of Luzhou Key Laboratory, The Affiliated Hospital of Southwest Medical University, Ministry of Education, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Chunxiang ZhangDepartment of Cardiology, Key Laboratory of Medical Electrophysiology, Ministry of Education, Institute of Cardiovascular Research, Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Nucleic Acid Medicine of Luzhou Key Laboratory, The Affiliated Hospital of Southwest Medical University, Ministry of Education, Southwest Medical University, Luzhou, 646000, Sichuan, China. zhangchx2021@163.com.
Qiuhong LiDepartment of Histology and Embryology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China. li-qiuhong@swmu.edu.cn.

Funding

Luzhou Science and Technology Bureau 2022YFS0627-A1Luzhou Science and Technology Bureau 2022YFS0630-B1National Natural Science Foundation of China U23A20398, 82030007Sichuan Science and Technology Program 2022YFS0578, 2022YFS0614Sichuan Science and Technology Program 2023NSFSC1840Sichuan Science and Technology Program 2024NSFSC0580Southwest Medical University 2021ZKMS005The Central Government Guides Local Science and Technology Development Project 2022ZYD0057
6 · The paper itself

Abstract

Fibrosis, caused by excessive extracellular matrix (ECM) deposition, is a major contributor to organ dysfunction and mortality. Tetraspanins (TSPANs) have emerged as key regulators of fibrotic processes across various organs. This review examines the roles of TSPANs (e.g., TM4SF5, CD151, CD63, and CD9) in fibrosis in the liver, heart, lungs, kidneys, skin, and cornea, focusing on their influence on fibroblast activation, epithelial-mesenchymal transition (EMT), inflammation, and ECM remodeling through TGF-β/Smad, STAT3, and integrin signaling. Potential TSPAN-targeted therapies, such as monoclonal antibodies, RNA silencing, and exosome engineering are also evaluated. Despite promising preclinical results, challenges remain in tissue specificity, delivery, and clinical application for TSPAN-based antifibrotic therapies.

Indexed as

FibrosisTetraspaninsAnimalsEpithelial-Mesenchymal TransitionExtracellular MatrixHumansSignal TransductionTetraspaninsEpithelial-Mesenchymal transitionExtracellular matrixOrgan fibrosisTetraspaninsTherapeutic perspectives

Identifiers

PMID40993816
PMCPMC12462079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.